The silver(I) complex 
INTRODUCTION
The potent antibacterial properties of silver compounds have been known for some time. For example, silver sulfadiazene has been used as a topical burn treatment to prevent bacterial infection.I, 2 and has been reported to have antifungal, antiherpes virus and antitreponemal activity. 3 [Ag(dppe)2]NO3 and [Ag(depe)2]NO3 were also found to have antibacterial and antifungal activity against C. albicans with activity comparable to fungizone, in a defined medium. 4 However, the antifungal activity was lost in Sabouraud's broth medium, as was the antitumour activity in media containing fetal calf serum. This illustrates a general problem with the development of silver compounds as drugs, viz. their reactivity in physiological fluids, with strong binding to components of the fluid, or sometimes precipitation of Ag(I) salts such as AgCI preventing uptake of silver. The success of silver sulfadiazene, which is polymeric in the solid state with distorted trigonal bipyramidal coordination geometry, 2 is attributed to the slow release of Ag(I) ions which function as the bactericide at the wound site. 5 The development of resistance to antibacterial silver preparations appears to be related to the ability of resistant bacteria to bind silver more strongly than chloride, 6 and hence the silver is unavailable to these bacteria.
Of the 100 silver compounds reported to have been tested by the National Cancer Institute for anticancer activity, only 5 had marginal activity at best. 7 Interestingly, the binuclear silver complex [(l-dppe)(AgNO3)2] was inactive against P388 leukemia cells, 8 which may be due to the increased kinetic reactivity of the linear silver complex compared to the tetrahedral complex. In an attempt to overcome these difficulties, some success has been achieved in reducing the kinetic reactivity of silver(I) complexes by imposing tetrahedral geometry at the metal centre, which tends to shield the metal from competing ligands, 7 thereby potentially allowing better access of the silver complex to the target site. Tetrahedral Ag(I) diphosphine complexes have been shown to be both Ph2PCH2CH2PPh2 (dppe); Et2PCH2CH2PEt2 (depe); cis-Ph2PCH=CHPPh2 (dppey)} are cytotoxic towards B16 melanoma cells in vitro with IC50 values of ca. 4 #M (IC50 is the concentration required to inhibit cloning efficiency by 50 %), which is comparable to the extensively studied Au(I) analogue.
The complexes were also active against intraperitoneal P388 leukemia in mice and M5076 reticulum sarcoma. 4 Cancer cells frequently possess respiratory defective mitochondria, 9 and it has been suggested that these may prove to be potential targets for novel antitumour agents. 10 (12) 2033 (4) 589 (4) 6646 (3) 27(1) C (13) 1594 (4) 834 (4) 7318 (3) 29(1 C (14) 1032 (4) 1603 (4) 7508 (3) 28(1 C (15) 903 (3) 2137 (4) 7035 (2) 25(1 C (16) 1361 (3) 1901 (3) 6361 (2) 21(1) C (17) 1694 (4) 4075 (4) 6788 (3) 33(1 C (18) 1660 (5) 4962 (4) (121) 1780 (4) 2665 (4) 1537 (3) 29(1) C (122) 2250 (4) 1985 (4) 1773 (3) 33(1) C (123) 2600 (4) 2150 (4) 2486 (3) 32(1 C (124) 2516 (3) 2976 (4) 2970 (2) 24(1) C (125) -117(3) 2143(4) 5300(3) 30(1) C (126) 75 (4) 1207 (4) 4796 (3) 28(1 C (127) 4807 (3) 2611 (4) 4512 (3) 28(1) C (128) 4326 (3) 2826 (4) 3825 (3) 29(1 C (129) 74 (4) 1342 (4) 3315 (3) 32(1 C (130) -280 (5) 2308 (4) 3483 (3) 44(2) C (131) 966 (4) -113(4) 3761(3) 34(1) C (132) 1646 (6) -443 (6) 3118 (4) 76(2) C (133) 4627 (4) 1881 (5) 5734 (3) 52(2) C (134) 4259 (5) 2679 (5) 6277 (3) 59(2) C (135) 4680 (4) 689 (4) 4342 (3) 44(2) C (136) 4625 (5) 478 (5) 3526 (3) 59(2) Ag (2) 2964 (1) 7526 (1) 112 (1) 21(1) P (21) 1881 (1) 6297 (1) 367 (1) 19(1) P (22) 4157 (1) 7224 (1) -929(1) 19(1) P (23) 1310 (1) 8292 (1) 88 (1) 25(1) P (24) 4479(I) 8299 (1) 843 (1) 21(1) N (21) 7675 (4) 9246 (4) 393 (2) 39 (1) O (21) 7084 (3) 9740 (3) 161 (3) 58 (1) (230) 945 (6) 7613 (7) -1412(4) 90(4) C (231) 1074 (7) 9348 (6) 705 (6) 117(4) C (232) 680 (14) 9603 (8) 1262 (6) 249 (11 C(233) 4903 (4) 8114 (4) 1722 (3) 30(1) C (234) 5955 (4) 8482 (5) 2034 (3) 40(2) C (235) 4661 (4) 9501 (4) 966 (3) 28 (1) C (236) 4027 (4) 10071 (4) 1554 (3) 44 (2) Ag-P(1) Ag-P(2) Ag-P(3) Ag-P(4) P(1)-C(25) P(2)-C(28) P(3)-C(26) P(4)-C(27) C(25) C(26) C(27) C(28) The second phase of the testing protocol involved the assessment of the mutagenicity of the silver compound. Here the yeast cultures were grown on a fermentable medium (containing glucose), and were then screened for induction of the well known mitochondrial mutation petite. This is a mitochondrial mutation which arises with a high spontaneous frequency (about 1%) and is characterized by the loss of segments of mitochondrial DNA, presumably through a defect in the replication mechanism. 14 This results in failure of cytochromes a + a3 and b to be synthesized by the mitochondrial system. As noted earlier, growth of petite cells can proceed on glucose medium until the glucose is depleted, after which time no growth is possible. This results in small white colonies of the petite mutation, rather than the larger creamy colonies of normal cells. Identification of these is unambiguous, the white colour is due to the lack of cytochromes a + a3 and b in these cells. [Ag(eppe)2]NO3 induced a high frequency of the petite mutation (Figure 1 ). When aspirin was present in the growth medium with the silver complex, the cells grew normally, and both the toxic and mutagenic effects of the silver compound were lost. Although the reasons for this are unclear, it is an effect that has been observed in previous studies of antimitochondrial compounds in our system. 29 it is suggested that aspirin prevents the penetration of the compounds into the cell by altering membrane permeability, thus protecting the mitochondria.
The related Au(I) 31 In rabbits this also occurred and ATP synthesis was shown to be reduced and mitochondrial defects were evident, eventually leading to death by cardiotoxicity. 32 Similar results were obtained in a pre-clinical trial of [Au(dppe)2] lactate, which was terminated due to cardio-, hepato-and vascular toxicity. 33 Although mitochondria appear to be a target site for the Au(I) complexes, our studies indicate that these complexes are not mitochondrially selective. It is also noteworthy that the [Au(dppe)2]CI concentrations of 12.5-100 #M used in the isolated rat mitochondria studies were much higher than those used in our yeast studies (< 12.5 #M). Therefore it is possible that the acute toxicity observed for [Au(dppe)2]CI is related to the relatively high dose administered. As [Ag(eppe)2]NO3 is antimitochondrially-active at much lower doses, it may prove to be a more useful chemotherapeutic agent. The higher activity may also be related to the higher water solubility of the silver complex compared to the gold complex, which should result in less accumulation in membranes and therefore greater potency. It is possible that Ag(I) complexes, particularly, [Ag(eppe)2]NO3, which show primary antimitochondrial toxicity, will be useful antitumour agents because they can attack the defective mitochondria of the tumour cells at sufficiently low doses, and destroy the tumour, with less damage being done to healthy cells. It is well known that cancer cells generally have low respiratory rates and high glycolytic activity. 9 The effect of aspirin in preventing the activity of anticancer drugs may be of importance clinically, since this analgesic is liberally prescribed for cancer patients undergoing chemotherapy.
CONCLUSIONS
The therapeutic use of silver compounds, at present, is limited to topical preparations for antiseptic purposes. The studies reported here show that tetrahedral silver diphosphine complexes, such as [Ag(eppe)2]NO3, show primary antimitochondrial activity, and may be useful as antitumour agents, selectively targeting the respiratory-deficient mitochondria in cancer cells. 9 The choice of ligands and metal appear to be important in controlling this activity. Although the reactivity of the silver compound with components of serum is noted, it may be possible to overcome this with a formulation which delivers the silver complex directly to cancer cells. In addition, the reversal of the effect with aspirin has obvious clinical implications.
